ANZCTR search results

The aim of this pilot study (n=20) is to better understand the impact of wood heaters on residential air quality as well as the effectiveness of portable air cleaners in improving indoor air quality and asthma and health symptoms. Indoor and outdoor air quality monitors will be placed in homes to measure fine particles in air (particulate matter (PM2.5) - this is a component of woodsmoke that results in poor air quality. We will also place small metal sampling tubes inside and outside your home to measure concentrations of volatile chemicals (volatile organic compounds (VOCs), which also contribute to poor air quality. Monitoring will be conducted for two months during winter. The air quality monitors transmit their data every 10 minutes to a secure cloud-based data repository.

The objective of this study is to demonstrate the safety and functionality of the Edwards 12F Sheath Introducer Set in conjunction with the Edwards SAPIEN X4 THV in subjects with symptomatic, severe, calcific AS. This is a prospective, single arm, multicentre, feasibility study that will include up to 30 subjects who have the 12F Sheath inserted at up to 5 sites in Australia and New Zealand. Subjects will be assessed at screening, procedure, post-procedure, discharge, and 30 days. Expected enrolment duration is approximately 6 months, resulting in a total study duration of approximately 9 months.

This research will conduct a randomized controlled trial (RCT) of the Growing Minds Check-In (GMCI-P) for parents, a universal online child mental health check-in and referral tool, that involves parents answering a set of questions about their child’s social, emotional and behavioural wellbeing (wellbeing), receiving automated feedback based on their responses to the questions and recommendations for evidence-based programs and information matched to their child’s needs.

‘GLY-200' is an orally-administered, pH-dependent, gut-restricted therapeutic polymer developed by Glyscend Therapeutics. GLY-200 interacts with the mucus on the surface of the duodenum (the first part of the small intestine) to form a temporary barrier that lasts several hours. This mimics the effects of gastric bypass surgery – a very effective surgical procedure for type 2 diabetes and obesity – where the duodenum is removed from contact with meal contents. We don’t fully understand how excluding the duodenum from contact with nutrients results in lowering of blood glucose or body weight, but possible mechanisms include slowing of stomach emptying or passage of contents through the small intestine, reduction in glucose absorption from the duodenum, or changes in the levels of hormones secreted by the small intestine. This study is designed to investigate these possible mechanisms, in both healthy volunteers and people with type 2 diabetes treated only with diet or metformin.

This research project is based at Eating Disorders Victoria (EDV) and embeds a master of clinical psychology placement program for postgraduate psychology students within a research program examining evidence-based eating disorder assessment and treatment. (Master Research Agreement attached) This is a pilot and feasibility RCT with two primary aims: (i) to explore the viability of running a full RCT to compare treatment efficacy and cost effectiveness of a stepped-care model of eating disorder treatment, specifically comparing two interventions; Cognitive Behaviour Therapy (CBT-E) and Guided Self Help (GSH); and (ii) to explore the feasibility of providing specialised training in eating disorder treatment and access to treatment via a community-university partnership that embeds professional psychology training in an ongoing research and treatment program. It is expected that eating disorder symptoms will be significantly reduced from pre- to post-treatment in both CBT-E and GSH. It is also expected that those allocated to the CBT-E group will have significantly lower eating disorder symptoms post-treatment compared to those allocated to GSH.

We are verifying if rectal swabs are as accurate as builk faeces testing in routine clinical care. We hypothesise that these two tests are equally as accurate and it would mean that it is easier to obtain medical tests for gastrointestinal organisms during routine clinical care.

The research team partnered with Surf Life Saving Australia (SLSA), Life Saving Victoria (LSV), and local council to co-design a learning-focused intervention. Learning had been identified through a pilot study conducted in 2021, in which beachgoers requested skills and opportunities for learning from the beach safety sector. The themes and best practices to be covered in the lesson were drawn from the pilot study, the literature, and then discussed amongst the research team and representatives of the risk sector, including those overseeing lifeguards in the case study region. The lifeguards to participate in the lesson were invited to contribute to these discussions but, being predominantly young university students, were unavailable. A finalized list of 19 actions were identified and incorporated into development of the lesson and into the codebook for measuring impact.

This is A double-blind, placebo-controlled, First-in-Human Study study to assess the safety ofZE50-0134, and how this drug acts in the body in healthy volunteers. ZE50-0134 may be indicated for use in patients with chronic lymphocytic leukaemia (CLL), but a trial of the drug in healthy volunteers is needed before trials in cancer patients can proceed. Who is it for? You may be eligible for this study if you are aged 18 to 55 years and are in good general health without a clinically significant medical history. People who have been diagnosed with cancer will not be eligible for this study. Study details All healthy volunteer participants who choose to enrol in this study will be assigned by chance to receive either a single dose of ZE50-0134 or placebo. All participants will have their vital signs checked (heart rate, blood pressure, temperature, etc), and will provide blood and urine samples for testing. If the drug appears safe, additional participants will be assigned by chance to receive a larger single dose of ZE50-0134 or placebo, followed by blood and urine testing. This will continue until a maximum safe dose is determined. It is hoped this research will determine the maximum dose of ZE50-0134 that can be administered safely without causing severe reactions. Once the dose of ZE50-0134 has been determined in healthy volunteers, a trial investigating the efficacy of ZE50-0134 as a treatment for patients with CLL may proceed.

Respiratory disease is the most common reason for admission to a NICU. Unfortunately, our understanding of how many respiratory therapies used in the NICU help babies lungs is poor. Broadly, we will create a large registry of lung function data during common NICU respiratory events and diseases. By doing so we will be able to address some of the uncertainties in clinical care for babies born with respiratory failure, specifically how best to determine optimal levels of respiratory support and how to guide common respiratory interventions such as extubation and surfactant therapy. We hypothesise that by generating a greater understanding of the relationship between a baby's lung disease and NICU respiratory care we will provide the tools to allow clinicians to improve respiratory care.

This is a substudy of the PRECISION-ITS trial. This study involves developing and evaluating a pharmacogenomics education/implementation program for pharmacists in Australia, The program will be developed by a multidisciplinary working group consisting of healthcare professionals, consumers and patients/carers with lived experience. Surveys assessing the knowledge, attitudes, perceptions and acceptability of pharmacogenomics amongst consumers and healthcare professionals in the adult and paediatric oncology setting will be used to inform the program's design. Who is it for? .You may be eligible to complete the survey(s) if you have received or cared for an adult or child who received treatment for cancer in Australia and are aged 15 years or above; or are a healthcare professional working in adult or paediatric oncology within Australia. Study details The program will be delivered to pharmacists at sites participating in the primary PRECISION-ITS trial. You may be eligible to participate in the program if you are a pharmacist at a regional Victorian hospital that is participating in the primary PRECISION-ITS trial. The program will focus on pharmacogenomics in adults receiving systemic anticancer therapies and implementing a pharmacogenomics service at participating sites in regional Victoria. The program will be evaluated by implementation science frameworks and participant end-user surveys. It is hoped that this research project will: address pharmacists' education needs in pharmacogenomics and establish a framework for wider implementation to other healthcare professionals and craft groups. It is hoped that this program will also facilitate pharmacogenomics knowledge translation into clinical practice, providing opportunities for rapid pharmacogenomics workforce capacity building, scalability and community acceptance beyond the trial.